German 'magic mushroom' biotech Atai jumps 13% in Nasdaq debut

AtaiBeckley

18/06/2021 18:40

** Shares of Germany's Atai Life Sciences B.V.  ATAI.O  up
13% at $16.9 after their U.S. stock market debut on Friday
    ** Shares opened at $21, 40% higher than IPO price of $15
per share  urn:newsml:reuters.com:*:nL3N2O03DU
    ** Co sold 15 mln shares in IPO, raising about $225 mln
    ** At the opening price, co was valued at around $3.19 bln
    ** ATAI is exploring the use of psychedelic treatments such
as psilocybin, the psychedelic active compound in magic
mushrooms, for mental illnesses
    ** Co was co-founded by German investor Christian Angermayer
and is backed by billionaire investor Peter Thiel
    ** Credit Suisse, Citigroup, Cowen and Berenberg were the
lead underwriters for the offering

 (Reporting by Sohini Podder in Bengaluru)
 ((sohini.podder@thomsonreuters.com))